Premium
Nefazodone in out‐patient treatment of inhaled cocaine dependence: a randomized double‐blind placebo‐controlled trial
Author(s) -
Passos Sonia Regina Lambert,
Camacho Luiz Antonio Bastos,
Lopes Claudia S.,
Borges dos Santos Maria Angélica
Publication year - 2005
Publication title -
addiction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.424
H-Index - 193
eISSN - 1360-0443
pISSN - 0965-2140
DOI - 10.1111/j.1360-0443.2005.01041.x
Subject(s) - nefazodone , placebo , abstinence , cocaine dependence , randomized controlled trial , medicine , adverse effect , anesthesia , psychology , psychiatry , addiction , receptor , alternative medicine , pathology , serotonin , fluoxetine
Aims To assess the efficacy of oral nefazodone in the treatment of cocaine dependence. Design A 10‐week randomized double‐blind clinical trial was performed. Methods All 210 subjects fulfilled Diagnostic and Statistical Manual version IV (DSM‐IV) criteria for cocaine dependence and were assigned randomly to 300 mg/day of oral nefazodone (N) or placebo (P). Self‐reported drug use, retention interval in treatment, adherence to prescription and depressive symptoms were assessed by the Hamilton scale. Findings Abstinence from cocaine for 3 weeks or more was achieved by 49.5% (N) and 45.7% (P) ( P = 0.58), but 16.2% (N) and 22.9% (P) used other drugs during abstinence. The average interval to resumption of drug use was 33.9 days (N) and 36.1 days (P). Adverse effects were reported by 45.8% (N) and 29.5% (P) ( P = 0.01). Treatment for these events was needed more often in N (24.0%) than in P (9.5%) ( P < 0.02). Conclusions These results do not support the indication of nefazodone for out‐patient treatment of inhaled cocaine dependence with or without other associated drug dependence diagnoses.